Real-time, point-of-care testing

at the tip of your tongue



GBS Inc.

CORPORATE PRESENTATION

January 2022

LEGAL

FORWARD LOOKING STATEMENTS

Certain statements in this presentation may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (“SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of GBS, Inc. and its affiliates (“GBS”) or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words “plan,” “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “may,” “will,” “would,” “could,” “should,” “seeks,” or “scheduled to,” or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws.

GBS cautions that any forward-looking statements made by GBS are not guarantees or indicative of future performance. Although GBS believes that its plans, cost estimates, returns on investments, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any forward-looking statements. GBS’s future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties. GBS does not have, nor undertake, any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

These materials are not intended as an offer or solicitation with respect to the purchase or sale of any security and may not be reproduced or redistributed in whole or in part to any other person. Recipients should seek appropriate independent professional advice prior to relying on, or entering into any commitment based upon materials.

All information included in this presentation is based on continuing operations, unless otherwise noted.

Investment Highlights

GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care.

Pioneering diagnostic platform adaptable to large unmet markets with multiple applications and indications

Point-of-care tests for layman and professional use, giving actionable, real-time results

Lead Products:

1) **Saliva Glucose** test is intended to make finger pricking and other forms of glucose monitoring obsolete
2) **Saliva SARS-CoV-2 Antibody** test provides real-time quantitative results to SARS-CoV-2 (COVID-19) virus

Identified 130+ additional test indications around biochemistry, immunology, tumor markers and endocrinology

Experienced Management and Advisory Board members with deep industry expertise

Highly Qualified & Experienced Leadership Team

Dr. Steven Boyages
M.D., MB, BS, Ph.D.
Interim
Chief Executive Officer
Chairman of the Board

Dr. Boyages is a practicing clinician in endocrinology with 30+ years' experience in medicine, including multiple executive positions.

Spiro Sakiris
Chief
Financial Officer

Mr. Sakiris has 32 years' experience in accounting, taxation, IPOs, capital raising, and business system designs, including the application of IFRS and US GAAP for the life science industry.

Prof. Paul Dastoor
Inventor,
Scientific Advisory Board

Prof. of Physics in the School of Mathematical & Physical Sciences and the Director of the Priority Research Centre for Organic Electronics at the University of Newcastle in Australia.

Prof. Jonathan Sessler
Board of
Directors

Prof. Sessler is well known for his ground-breaking work on expanded porphyrins and their applications to biology and medicine.

WESTMEAD HOSPITAL

EY

THE UNIVERSITY OF NEWCASTLE AUSTRALIA

THE UNIVERSITY OF TEXAS AT AUSTIN

Our Saliva Glucose Biosensor technology will make finger pricking obsolete.



- ✓ Pain-free
- ✓ Non-invasive
- ✓ Easy to use
- ✓ Convenient

Large & Growing Total Global Addressable Market

Market Facts and Figures[1]

The total number of people with diabetes is predicted to rise to **643 million** (1 in 9 adults) by 2030 and **784 million** (1 in 8 adults) by 2045.

4 in 5 people with diabetes (81%) live in low income and middle-income countries.

Diabetes caused **6.7 million** deaths in 2021 – 1 every 5 seconds.

An estimated **44%** of adults living with diabetes (**240 million** people) are undiagnosed. Almost **90%** of these people live in low income and middle-income countries.

537 million adults (20-79 years) are living with diabetes worldwide – 1 in 10.

Diabetes was responsible for an estimated USD **966 billion** in global health expenditure in 2021. This represents a **316%** increase over the last 15 years.

541 million adults worldwide, or **1 in 10**, have impaired glucose tolerance, placing them at high risk of developing type 2 diabetes.

68% of adults with diabetes live in the 10 countries with the highest number of people with diabetes.

1 International Diabetes Federation Atlas 10th edition –Global Fact Sheet 2021

GBS Inc. Will Benefit From Sales and Distribution

The Company will financially benefit from sales and synergy of development of the Biosensor Platform in multiple regions.

GBS Inc.

Global: The SARS-CoV-2 Antibody Biosensor test.

Asia Pacific: The Saliva Glucose Biosensor.

BioSensX North America

GBS, Inc. owns a 50% interest in BioSensX N.A.

North American (US & CAN):
Saliva Glucose Biosensor and all additional Dx tests in development

- → Diabetes is the 7th leading cause of death in the United States
- → Medical costs and lost work/wages for people with diagnosed diabetes total $327 billion yearly in the US

*2021 Diabetes Fast Facts-Centers for Disease Control &Prevention

Asia Pacific Region Market Opportunity

Highlights

- 1 in 8 adults have diabetes – 206 million.
- The Western Pacific Region accounts for over a third (38%) of the total number of adults living with diabetes.
- China accounts for 1 in 4 of all adults living with diabetes in the world.
- Over half (53%) of adults living with diabetes are undiagnosed.
- Diabetes is responsible for 2.3 million deaths in 2021 – the highest number of all IDF Regions.
- Diabetes-related expenditure in 2021 totals USD241 billion – 25% of global expenditure.
- 1 in 7 live births are affected by hyperglycemia in pregnancy.

International Diabetes Federation Atlas 10th edition –Global Fact Sheet 2021

Our Technology: The Biosensor Platform

The Biosensor is a platform technology that can be modified to create multiple real-time, non-invasive diagnostic tests.



A small, printable organic strip, the Biosensor Platform is designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.

The core architecture of the Biosensor is patented Organic Thin Film Transistor (OTFT) technology, which can be printed at scale, at a low cost.

Currently have identified a pipeline of up to 130 indications, ranging from glucose for diabetes management, to immunological conditions and communicable diseases.

The Saliva Glucose Biosensor is a Precise and Accurate Solution for Measuring Glucose in Saliva

Organic Thin Film Transistor (OTFT) Technology.



The Biosensor exhibits a linear glucose response at concentrations **100 times more sensitive than commercial blood glucose sensors[1].**

This groundbreaking innovation enables the detection of glucose concentrations in ranges physiologically relevant in saliva.

1 Elkington, D. & Belcher, Warwick & Dastoor, Paul & Zhou, Xiaojing. (2014). Detection of saliva-range glucose concentrations using organic thin-film transistors. Applied Physics Letters. 105. 043303. 10.1063/1.4892012.

The Biosensor can be Modified to Create Multiple Diagnostic Tests

The top layer of the Biosensor is easily modified to detect a range of analytes.

Saliva Glucose Biosensor

To monitor glucose levels in saliva in people living with diabetes.



SARS-CoV-2 Antibody Test

To monitor exposure, infection and immunity for COVID-19.



A: By substituting the detection element (region A) of the Biosensor depending on the analyte to be detected, the Biosensor can be modified to monitor a wide range of saliva-based diagnostic analytes (e.g. Glucose Oxidase for monitoring glucose in saliva, SARS-CoV-2 antigen-specific antibodies to monitor exposure, infection and immunity for COVID-19). The core OTFT sensing element and mode of action of the platform remains the same.

Biosensor Platform Pipeline Addressable Markets

The Biosensor can be modified to create over 130 real-time, non-invasive diagnostic tests



With our world-first Biosensor Platform technology, GBS Inc. will complete the development, and if successful in its regulatory approval, it will launch two urgently needed non-invasive, real-time diagnostic tests.

1

The Saliva Glucose Biosensor, the first non-invasive replacement for finger-prick blood testing for people with diabetes.

Development partners

Johns Hopkins University

The University of Newcastle Australia

2

The SARS-CoV-2 Antibody Biosensor, to test exposure, infection and immunity in the fight against COVID-19.

Development partners

Wyss Institute

The University of Newcastle Australia

As Easy to Use as Placing a Stick of Gum on Your Tongue

The Biosensor detects the analyte (e.g. glucose or viral antigen/antibody) in saliva and emits a signal to an individual's smart device, activating the app to display an individual's analyte reading.

1

Place the Saliva Glucose Biosensor in contact with saliva.

2

With the Biosensor nearby, the digital app will display glucose levels, flagging any results that need attention.

3

The app provides real-time data and sends data to the electronic medical record or caregiver, as assigned by the user.

For illustrative purposes only and has yet to receive regulatory approval in any jurisdiction.

GBS, Inc. Recent and Upcoming Expected Milestones

IP Overview

Our licensed Biosensor technology is patent protected through to 2033.

Official Number	Status	Jurisdiction
9,766,199	Granted	United States 
ZL201380022888.2	Granted	China 
AU2016/050555	Filed	Australia 

The patent portfolio is being globally expanded as the technology candidates necessitate patent protection throughout product development.

Financial Snapshot

Headquarters

New York City

Sector / Industry

Healthcare
Medical devices

Ticker / Exchange

GBS / NASDAQ-GM

IPO Date

December 23, 2020

IPO Size

$21,600,000

Common Stock Issued

14,882,522

Warrants Issued

7,263,363 ($8.50-$17.00)

Financial Highlights

GBS Inc. continues to be fiscally responsible and leverage multiple tools and strategies to extend its cash runway through sublicenses and collaborations which have provided a diverse set of financing opportunities to the Company.

Financials as of September 30, 2021

Cash, cash equivalents & marketable securities totaled approximately $12.6M

GBS expects based on the current operating plan and financial resources, its cash, cash equivalents and marketable securities at September 30, 2021, will be sufficient to cover expenses and capital requirements into the first half of 2023.

Recognition from the Australian Federal Government

Awarded $4.7M (USD) grant from the Australian Federal Government to fund the buildout of a high-tech biosensor manufacturing facility solely for GBS's manufacturing and development

- ✓ Identified by the AU Government as one of only six National Manufacturing Priorities under its Modern Manufacturing Strategy

Recent Corporate Achievements

Building off a year development and positioning

Additional Recent Developments

- ✓ FDA pre-submission for Saliva Glucose Biosensor
- ✓ FDA Breakthrough application filed for Saliva Glucose Biosensor
- ✓ Clinical validation study conducted at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The objective of this study was to develop an electrochemical assay to detect SARS-CoV-2 IgG in human plasma

  The statistical design was powered in accordance with this study objective. Preliminary findings were:

  - ❖ The SARS-CoV-2 Antibody biosensor assay was 100% sensitive and 100% specific using positive and negative SARS CoV-2 human plasma samples
  - ❖ The time in obtaining results was less than 10 minutes

Upcoming Milestones for CY 2022

Calendar Year 2022 Milestones:

- ✓ Complete clinical salivary collection and clinical trial protocols with Johns Hopkins Bloomberg School of Public Health
- ✓ Secure strategic sublicensing partnership for sales and distribution in the Asia Pacific Region
- ✓ Identify manufacturing facility site location
- ✓ Execute the proposed three step clinical plan
    1. Generation of prospective data, the initial objective is to explore the relationship between salivary glucose and plasma glucose as well as the time course between the two sample types
    2. Development of the algorithm between plasma and salivary glucose
    3. Confirmation of the algorithm and data generation for regulatory submission

GBS Inc.

On a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care.



Thank you